“Chimpanzee Adenovirus Vector Ebola Vaccine.”. N Engl J Med 376 (10). N Engl J Med: 928-938. doi:10.1056/NEJMoa1410863.
. 2017. “Phase 1 Study Of Pandemic H1 Dna Vaccine In Healthy Adults.”. Plos One 10 (4). Plos One: e0123969. doi:10.1371/journal.pone.0123969.
. 2015. “Safety And Immunogenicity Of Dna Vaccines Encoding Ebolavirus And Marburgvirus Wild-Type Glycoproteins In A Phase I Clinical Trial.”. J Infect Dis 211 (4). J Infect Dis: 549-57. doi:10.1093/infdis/jiu511.
. 2015. “Safety And Immunogenicity Of Ebola Virus And Marburg Virus Glycoprotein Dna Vaccines Assessed Separately And Concomitantly In Healthy Ugandan Adults: A Phase 1B, Randomised, Double-Blind, Placebo-Controlled Clinical Trial.”. Lancet 385 (9977). Lancet: 1545-54. doi:10.1016/S0140-6736(14)62385-0.
. 2015. “Safety And Tolerability Of Chikungunya Virus-Like Particle Vaccine In Healthy Adults: A Phase 1 Dose-Escalation Trial.”. Lancet 384 (9959). Lancet: 2046-52. doi:10.1016/S0140-6736(14)61185-5.
. 2014. “Prime-Boost Interval Matters: A Randomized Phase 1 Study To Identify The Minimum Interval Necessary To Observe The H5 Dna Influenza Vaccine Priming Effect.”. J Infect Dis 208 (3). J Infect Dis: 418-22. doi:10.1093/infdis/jit180.
. 2013.